---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028296"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:43:22.274199+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma gets IRB approval for Phase 1b norovirus challenge study with CDI-988; enrollment starts Q1 2026

## Summary
- IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
- Enrollment expected to begin Q1 2026; study involves up to 40 healthy subjects ages 18-49.
- CDI-988 is first oral broad-spectrum antiviral for norovirus; no approved treatments or vaccines currently exist.
- Study is randomized, double-blind, placebo-controlled; primary endpoint is reduction in clinical symptoms.
- Follows prior FDA clearance of IND and favorable Phase 1 safety data from August 2025.

## SEC filing metadata
- accession: 0001493152-25-028296
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/0001493152-25-028296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315225028296/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028296
- JSON: https://secwatch.observer/filing/0001493152-25-028296.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.